


RECEIVED

APR 18 2002

TECH CENTER 1600/2900

Application No.: 09/660,302



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



RECEIVED

APR 18 2002

TECH CENTER 1600/2900

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Strous et al.

**Serial No.:** 09/660,302

**Filed:** 9/12/2000

**For:** CONTROLLING AVAILABILITY OR  
ACTIVITY OF PROTEINS BY USE OF  
PROTEASE INHIBITORS OR RECEPTOR

**Confirmation No.:** 6944

**Examiner:** T. McKelvey

**Group Art Unit:** 1636

**Attorney Docket No.:** 2183-4525US

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being sent via Federal Express on the date of deposit shown below addressed to the U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202.

April 15, 2002

Date

*Lynette Eliason*

Lynette Eliason  
Name (Type/Print)

**STATEMENT UNDER 37 C.F.R. §§ 1.821 THROUGH 1.825**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


I, Andrew F. Nilles, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), are included herewith to comply with the requirements of 37 C.F.R. §§ 1.821 and/or 1.825 as requested by the Examiner.

Serial No.: 09/660,302

2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be the same as the paper copy of the substitute SEQUENCE LISTING.
3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,



Andrew F. Nilles  
Registration No. 47,825  
Attorney for Applicant(s)  
**TRASKBRITT, PC**  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: April 15, 2002  
AFN/bv